Page 2 of 12 – SEC Filing SCHEDULE 13D CUSIP No. 04351P101 Page 2 of 12 Pages
1 NAME OF REPORTING PERSONS OrbiMed Advisors LLC 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) o (b) o 3 SEC USE ONLY 4 SOURCE OF FUNDS (See Instructions) AF 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) o 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 0 8 SHARED VOTING POWER 3,671,976 9 SOLE DISPOSITIVE POWER 0 10 SHARED DISPOSITIVE POWER 3,671,976 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,671,976 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) o 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 14.6%* 14 TYPE OF REPORTING PERSON (See Instructions) IA
* This percentage is calculated based upon 25,193,221 of the Issuer’s Ordinary Shares outstanding (including any such Ordinary Shares represented by ADSs (as defined below)), as set forth in Exhibit 1.1 to the Issuer’s Form 6-K dated June 10, 2016 and filed with the SEC (as defined below) on June 10, 2016. Follow Ascendis Pharma A/S
Follow Ascendis Pharma A/S
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
SCHEDULE 13D
| CUSIP No. 04351P101 | Page 2 of 12 Pages |
| 1 | NAME OF REPORTING PERSONS OrbiMed Advisors LLC | |||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) o (b) o | | ||
| 3 | SEC USE ONLY | |||
| 4 | SOURCE OF FUNDS (See Instructions) AF | |||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) | o | ||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 0 | ||
| 8 | SHARED VOTING POWER 3,671,976 | |||
| 9 | SOLE DISPOSITIVE POWER 0 | |||
| 10 | SHARED DISPOSITIVE POWER 3,671,976 | |||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,671,976 | |||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) | o | ||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 14.6%* | |||
| 14 | TYPE OF REPORTING PERSON (See Instructions) IA | |||
* This percentage is calculated based upon 25,193,221 of the Issuer’s Ordinary Shares outstanding (including any such Ordinary Shares represented by ADSs (as defined below)), as set forth in Exhibit 1.1 to the Issuer’s Form 6-K dated June 10, 2016 and filed with the SEC (as defined below) on June 10, 2016.
Follow Ascendis Pharma A/S
Follow Ascendis Pharma A/S
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
